Biktarvy vs Calquence
Side-by-side drug price comparison from Medicare Part D data
Verdict
Biktarvy costs 63% less per claim than Calquence ($3746.00 vs $10105.00). Calquence has a generic alternative available. Total Medicare spending: Biktarvy at $3.8B vs Calquence at $2.9B.
| Metric | Biktarvy | Calquence |
|---|---|---|
| Avg Cost per Claim Average cost Medicare pays per prescription claim | $3,746* | $10,105 |
| Total Medicare Spending Total Medicare Part D spending on this drug | $3.8B | $2.9B |
| Total Claims | 1,020,000 | 286,000 |
| Year-over-Year Change Price change from prior year (lower is better for patients) | 12.8%* | 34.2% |
| Generic Available | No | Yes |
| Condition | HIV | Cancer |
| Total Beneficiaries | 85,000 | 28,000 |
Biktarvy costs 63% less per claim than Calquence ($3746.00 vs $10105.00). Calquence has a generic alternative available. Total Medicare spending: Biktarvy at $3.8B vs Calquence at $2.9B.
Explore More
The side-by-side above pulls the CMS Medicare Part D Drug Spending data data for both entity A and entity B. What follows is the interpretation — which specific axes carry the most weight for entity A versus entity B, and which differences are large enough to influence a real decision.
Practical use of the comparison: read the data above, then drill into the individual entity A and entity B detail pages for the underlying breakdown. A pairwise comparison answers the relative question; the per-entity pages answer the absolute question.
Source: CMS Medicare Part D Spending, 2026.